Cancer, Prostate
Conditions
Keywords
marker detection, blood sample
Brief summary
This is a category 3 human study, prospective, comparative, in parallel groups. A comparative qualitative and quantitative analysis of several markers in 250 samples is proposed.
Detailed description
The assumption is that researchers can engineer synthetic metabolic and genetic networks to expand the panel of molecules that are currently known to be detected by natural systems. The investigators also hypothesize synthetic metabolic and genetic networks can be tuned for decisions making and in particular to diagnose diseases from biomarkers detections. This project proposes for the first time a hybrid analogue / digital solution for the multiplexed detection of biomarkers using bacterial and paper-based biosensors. Biosensors can be designed using analog or digital devices. Digital devices in synthetic and natural systems are noise-resistant and useful for decision-making. Analog devices are useful for signal transmission and processing. Here the investigators take advantage of signal transmission and processing via analog transducers and adders, and then decision-making via genetic switches. Such a hybrid analogue / digital approach has not yet been developed for biosensing. Another novelty of the project is to use synthetic metabolic pathways to develop analog devices. The advantage in term of treatment, for example, consists in the fact that the speed of enzymatic reactions in an analog adder far exceeds the speed of gene expression required to create a genetic logic matrix; it becomes even more pronounced when the devices are connected in series. The methodology will be illustrated for the detection of biomarkers of prostate tumors, but it is broad enough to be applicable to other diagnoses. The choice to develop biosensors for prostate disease is of practical relevance since the current screening strategy (based on PSA measurement) can lead to overdiagnosis and cannot differentiate between patients with aggressive tumors and those with an indolent illness.This study propose to mainly develop a bacterial and paper-based biosensor system
Interventions
OTHERBlood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
assessed biomarker in clinical samples
Sponsors
MICALIS
CBS
University Hospital, Montpellier
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men aged over 18 * Informed, written consent of the patient for the biological collection * Subject affiliated to a French social security scheme or beneficiary of such a scheme Patients specific inclusion criteria : \- Admitted to care prostate disease or suspicion of prostate cancer and with a positive or negative PSA blood result Controls specific inclusion criteria : \- Man free from all prostate or bladder pathologies
Exclusion criteria
* Patient under legal protection * Persons deprived of their liberty, protected adults or vulnerable persons * Participants may withdraw their consent at any time and for any reason whatsoever without incurring any negative consequences without change in their usual care Controls specific non-inclusion criteria : * Patient with current prostatic or urinary infection * History of treatment for prostate cancer other than surveillance management
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ability to detect and quantify biomarkers such as PSA in samples using biosensors platform | Up to 69 months | The positive signal is bases on a permeation in E. coli cell membrane and recombinase switches. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigational biomarker panel for diagnosis / Creatinine | Baseline | Biospecimen retention: blood serum and urine (unit µmol/l) |
| Investigational biomarker panel for diagnosis / Sarcosine | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Spermine | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Ornithine | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Choline | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis /Taurine | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Prostatic specific antigen | Baseline | Biospecimen retention: blood serum and urine (unit mg/l) |
| Investigational biomarker panel for diagnosis / Serotonin | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Putrescine | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis /ribitol | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / inositol | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / 2-oxoglutarate | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis /citrate | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
| Investigational biomarker panel for diagnosis / Fumarate | Baseline | Biospecimen retention: blood serum and urine (unit: mg/l) |
Countries
France
Outcome results
None listed